ClinicalTrials.gov record NCT07173010
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital
Pediatric Arthropathy Beyond Inflammation: Clinical Spectrum and Diagnostic Approach at Assiut University Children Hospital
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This observational study looks at children (up to 18 years) with non-inflammatory joint disease seen at Assiut University Children Hospital. It combines a retrospective review of cases from the past three years with prospective evaluation of new patients over one year. Clinical details, laboratory results, and imaging will be collected to identify underlying causes and distinguish these disorders from inflammatory arthritis.
What it is studying. The study aims to identify the most common underlying causes of non‑inflammatory arthropathy in children by reviewing clinical findings, laboratory tests, and imaging.
What the researchers hope to learn. To identify which conditions most commonly cause non‑inflammatory arthropathy in children; to improve diagnostic accuracy; to help distinguish these conditions from inflammatory joint diseases; and to inform appropriate management and reduce misdiagnosis and unnecessary treatment.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
To identify the most common underlying causes of non-inflammatory arthropathy in children presenting to Assiut University Children Hospital for through clinical evaluation, laboratory testing, and imaging, in order to improve diagnostic precision, guide appropriate management, and distinguish these conditions from inflammatory joint diseases.
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Infants and children up to 18 years at diagnosis.
- Patients presents with picture of non inflammatory arthropathy as joint deformity, stiffness and skeletal abnormality (arthropathy) with normal inflammatory markers
Exclusion criteria
- Patients more than 18years.
- Patients presents with painful,hot, tender or red joints (Arthritis) associated with elevated inflammatory markers .
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
Arthropathy refers to any disease or abnormal condition of a joint. It includes both inflammatory ( arthritis) and non-inflammatory types. Arthritis involves joint inflammation with symptoms such as pain, swelling, and stiffness, along with elevated inflammatory markers. In contrast, non-inflammatory arthropathy may mimic arthritis but lacks signs of inflammation and typically shows normal inflammatory markers. Non inflammatory arthropathy can closely mimic juvenile idiopathic arthritis (JIA), leading to frequent misdiagnosis and inappropriate treatment. These disorders are sometimes incorrectly diagnosed and treated as JIA, patients often do not respond to immunosuppressive treatment, leading to poor compliance, disease progression, and unnecessary exposure to potentially harmful medications. A high index of suspicion, detailed clinical evaluation, and appropriate imaging are essential to distinguish these mimics from true inflammatory arthritis. Here's a breakdown of some conditions categorized as non-inflammatory arthropathies: Mucopolysaccharidoses (MPS) are rare inherited metabolic disorders caused by enzyme deficiencies that impair the breakdown of glycosaminoglycans (GAGs), leading to their accumulation and progressive tissue and organ damage. Patients often present with arthropathy ,joint stiffness alongside hallmark features such as skeletal abnormalities, developmental delays, intellectual disability, cardiac issues, corneal clouding, hearing loss, short stature, dysostosis multiplex, and coarse facial features.However Some attenuated forms of mucopolysaccharidoses (MPS), particularly MPS I (Scheie syndrome), MPS II (attenuated Hunter syndrome), and MPS VI (Maroteaux-Lamy syndrome), may present predominantly with joint stiffness and contractures without significant systemic or cognitive involvement. Progressive Pseudorheumatoid Dysplasia (PPRD) is a rare autosomal recessive skeletal disorder caused by mutations in the WISP3 gene, crucial for joint cartilage development and function. It leads to progressive degeneration of articular cartilage, primarily affecting the interphalangeal joints. Patients typically present with painless, progressive joint stiffness and enlargement without inflammation, joint contractures, gait abnormalities, and spinal deformities such as scoliosis or kyphosis, resulting in abnormal posture and muscle weakness-related morbidities. Camptodactyly-Arthropathy-Coxa Vara-Pericarditis (CACP) syndrome is a rare autosomal recessive disorder characterized by congenital or early-onset camptodactyly, non-inflammatory arthropathy with synovial hyperplasia, progressive coxa vara deformity of the hip, and non-inflammatory pericarditis. Joint effusions are typically cool and unresponsive to anti-inflammatory treatments. Idiopathic Multicentric Osteolysis is a rare autosomal dominant skeletal disorder characterized by progressive osteolysis primarily affecting the carpal and tarsal bones, leading to joint deformities, pain, and mobility loss. Typically presenting in childhood, patients experience arthritic-like episodes, progressive deformities, osteolytic changes on imaging, and varying degrees of disability. Associated features may include short stature, muscle weakness, cardiovascular abnormalities, chronic renal failure, as well as occasional mental retardation and minor facial anomalies. Infantile Systemic Hyalinosis (ISH) is a rare autosomal recessive fibromatosis caused by mutations in the ANTXR2 (CMG2) gene, resulting in widespread hyaline material deposition in multiple tissues including skin, joints, and internal organs. Clinically, ISH presents with painful joint contractures which may lead to arthrogryposis-like appearance (multiple joint contractures), Progressive stiffness and fixed flexion deformities develop especially in knees, elbows, hips, and fingers ,Limited range of motion,subcutaneous nodules, gingival hypertrophy, osteopenia, failure to thrive, protein-losing enteropathy with diarrhea, and recurrent infections. Farber disease is a rare, fatal autosomal recessive metabolic disorder caused by mutations in the ASAH1 gene, leading to deficient acid ceramidase enzyme activity and subsequent ceramide accumulation in tissues. Affected children typically present with progressive painful joint stiffness, limited motion, contractures, subcutaneous nodules, and hoarseness due to laryngeal involvement, which can result in breathing difficulties. Osteogenesis imperfecta (OI) is a genetic connective tissue disorder caused by mutations in the COL1A1 and COL1A2 genes, leading to defective type I collagen synthesis. Characterized by brittle bones with increased fracture risk and low bone density,Skeletal deformities and recurrent fractures contribute to abnormal joint mechanics, resulting in arthropathy, stiffness, reduced mobility, and functional impairment over time. OI also presents with blue sclerae, dentinogenesis imperfecta, short stature, and adult-onset hearing loss. Cardiovascular manifestations such as valvular insufficiencies and aortic root dilation have been reported. Milder symptoms include joint laxity, easy bruising, hernias, and hyperhidrosis.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
Some participants will be identified from records of the past three years; others are children who present newly during a one‑year period. The study involves clinical evaluation, laboratory testing (including inflammatory markers), and imaging to help determine the cause of non‑inflammatory arthropathy. The registry does not specify any additional invasive procedures beyond those clinical tests and imaging.
How the study is structured. An observational cohort, cross-sectional study that includes a retrospective review of cases from the last three years and prospective evaluation of newly presenting patients for one year. No treatments are assigned; the study collects and reviews clinical exams, laboratory tests, and imaging.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The registry lists this study under Mucopolysaccharidoses; Progressive Pseudorheumatoid Dysplasia; Farber Disease; Osteogenesis Imperfecta; Infantile Systemic Hyalinosis; Idiopathic Multicentric Osteolysis. Does it apply to my diagnosis?
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The registry says recruitment has not started. When is it expected to open, and can I register interest now?
- No sites are listed on the registry yet. Where will the study take place?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on Erdheim-Chester disease
Important dates
- Study start
- September 2025 (estimated)
- Primary completion
- September 2026 (estimated)
- Study completion
- October 2026 (estimated)
- Target enrollment
- 35 participants (estimated)
- Last updated on registry
- Sep 15, 2025
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Assiut University
- Principal investigator
- Nora Ammar Shawket, Principal investigator
Assiut University
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Nora Ammar Shawket 📞 +201129859299 ✉ nrnr87355@gmail.com
Participating sites
Study locations have not been posted on ClinicalTrials.gov yet. This study is not yet recruiting, so sites may be added when recruitment begins. The central study contact above may be able to tell you about planned sites.
Terms used on this page · explanations by MedicalUpdates.ai
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- immunosuppressive
- A medicine that reduces the activity of the immune system. Studies of autoimmune conditions often require a stable dose, a prior failure, or a washout of such medicines.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials